Somatic and Psychiatric Comorbidities of Hidradenitis Suppurativa in Children and Adolescents
Overview
Affiliations
Background: Hidradenitis suppurativa (HS) is associated with various somatic and psychiatric comorbidities. Data regarding comorbidities in young patients with HS are sparse.
Objective: We analyzed both somatic and psychiatric comorbidities in young patients in a nationwide HS cohort.
Methods: In this retrospective case-control study, data from cases of HS in young (age 5 to <18 years) patients and age-matched controls with benign melanocytic nevi were collected from the Finnish Care Register for Health Care. The prevalence of preselected comorbidities was compared between the HS and control groups.
Results: A total of 153 HS cases were found in the specified age group. Of these, 34.0% had at least 1 somatic comorbidity compared with 4.9% of the controls. At least 1 of the preselected psychiatric diagnoses was present before the age of 18 years in 15.7% of case patients with HS compared with in 5.6% of the controls. By the age of 23 years, 23.5% of the patients with HS and 8.7% of the controls had at least 1 identified psychiatric comorbidity.
Limitations: Despite this being one of the largest HS cohorts ever studied, the number of young patients with HS was relatively low. Because this was a registry-based study, it was not possible to verify the accuracy of the International Classification of Diseases codes.
Conclusion: Physicians should monitor young patients with HS for both somatic and psychiatric comorbidities.
Zhu Z, Wang X Discov Oncol. 2025; 16(1):304.
PMID: 40072688 PMC: 11904070. DOI: 10.1007/s12672-025-02075-4.
Common Dermatologic Disorders in Down Syndrome: Systematic Review.
Lam M, Lu J, Elhadad L, Sibbald C, Alhusayen R JMIR Dermatol. 2024; 5(1):e33391.
PMID: 39475820 PMC: 10334906. DOI: 10.2196/33391.
Vernero M, Saibeni S, Scalvini D, Cicalini C, Chiarello L, Nardi S J Clin Med. 2024; 13(4).
PMID: 38398332 PMC: 10889244. DOI: 10.3390/jcm13041019.
Hidradenitis Suppurativa in Children and Adolescents: An Update on Pharmacologic Treatment Options.
Chiang N, Sibbald C, Levy R, Lara-Corrales I Paediatr Drugs. 2023; 25(6):659-676.
PMID: 37782437 DOI: 10.1007/s40272-023-00595-6.
Hardin J, Murray G, Swerdel J JMIR Dermatol. 2023; 5(4):e38783.
PMID: 37632892 PMC: 10334943. DOI: 10.2196/38783.